Ending ‘Magical Thinking’ in Compounding

Consistent product quality requires a clear understanding of the essence of CGMPs. Experts fear that the message is not always getting through to compounders.

Pharmaceutical compounding recalls the earliest days of medicine making, when the mortar and pestle, and variability, were the rule. Since that time, and the establishment of the United States Pharmacopeia (USP) and FDA in the United States, the field has come a long way.

Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
October 2020
Pages: 46-51

Citation

When referring to this article, please cite it as A. Shanley, “Ending ‘Magical Thinking’ in Compounding," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).

Articles in this issue

almost 6 years ago

Article

Enhancing Process Validation for Sterile Liquid and Freeze-Dried Forms: Part 1

almost 6 years ago

Article

Enhancing Process Validation for Solid Oral Dosage Forms: Part 2

almost 6 years ago

Article

Due Diligence Assessment of CMC Activities

almost 6 years ago

Article

Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?

almost 6 years ago

Article

Tackling Cybersecurity Challenges in Legacy Systems

almost 6 years ago

Article

Viral Vector API Characterization of Product-Related Impurities

almost 6 years ago

Article

Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation

almost 6 years ago

Article

Strong Quality Culture: A How-To for Busy Managers

almost 6 years ago

Article

Resources, Guidelines, and Guidance Documents

almost 6 years ago

Article

Regulatory and Standard Setting Organizations

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.